Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent Canvaxin

Trial Profile

Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent Canvaxin

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2006

At a glance

  • Drugs Melanoma vaccine (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 07 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top